Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-X long-term open-label extension in systemic lupus erythematosus
2010-022101-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tabalumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Safety and tolerability of LY2127399. Started Apr 2012; status: completed.
02
Drugs
tabalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-022101-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022101-18.